Oxford Nanopore raises £31.4M for sequencing work; Chelsea maps out alternative paths for Northera;

 @FierceBiotech: Crazy or creative? MIT finance whiz suggests a twist on R&D funding drought: Bankroll it with risky derivatives Report | Follow @FierceBiotech

 @JohnCFierce: Merck KGaA had already dumped the 2055 pact it had with Idera on safety concerns. Now it flunks Phase II. Finished. Item | Follow @JohnCFierce

 @RyanMFierce: Ironic and idiotic. A call for open access to clinical trials data in a journal article locked behind a pay wall. Article | Follow @RyanMFierce

 @MarkHFierce: OTC cranberry capsule gains medical device status in Europe as a cure for bladder infections. A first, it seems. Release | Follow @MarkHFierce

> Oxford Nanopore, a British sequencing company, raised £31.4 million in additional funds. Story

> As it plans to meet with regulators soon, Chelsea Therapeutics ($CHTP) is mapping out a potential route to a more limited approval for Northera. Report

> Merck ($MRK) is partnering with Trevena in the search for biased ligands against an undisclosed receptor. Story

> Gilead Sciences ($GILD) has launched a late-stage study of GS-1101, its PI3K inhibitor for chronic lymphocytic leukemia. Story

Pharma News

 @FiercePharma: Sandoz's manufacturing slowdown/shortage in Quebec prompts calls for new government powers. Forced production, for one. News | Follow @FiercePharma

> Roche moves forward with injectable Actemra. More

> German gatekeepers nix GSK's lupus drug Benlysta. News

> Novartis now top dog in skin drugs with $1.5B Fougera buy. Story

Medical Devices News

 @FierceMedDev: DSM swoops in with $360M offer for Kensey Nash. News | Follow @FierceMedDev

> J&J buys first Chinese medical device company. Item

> Osprey makes successful landing on ASX. Article

> Covidien, GE Healthcare to blend patient monitoring system tech. Story

Pharma Manufacturing News

 @EricPFierce: Genzyme says the FDA and EMA have signed off a second fill-finish operation for a couple of drugs at the upgraded plant in Ireland. Report | Follow @EricPFierce

> Hospira says temporary production glitch affecting propofol supplies. More

> Workers killed in another API plant explosion. News

> Genzyme's $150M plant upgrade starts to pay off. Article

> Merck expands packaging plant to take on more vaccines. Story

CRO News

> Abbott, Syngene to open first R&D nutrition center in India. Item

> Synexus grabs Osteomed as its interest in Poland grows. Story

> What did the top CRO CEOs earn last year? Article

> Parexel experiences huge revenue and backlog growth in Q3. More

Vaccines News

> 'Designer' lymph nodes could boost cancer vaccines. Story

> Japan OKs Sanofi's inactivated polio vaccine. News

> Mucosis nasal flu vaccine shows positive results in animals. Report

> Ampligen-FluMist nasal trial begins. Article

And Finally… After allaying the federal government's fears, researchers have published one of two studies examining how they engineered bird flu to become more virulent. Some experts had been considering that the research could be a tool in the hands of terrorists. Story

 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.